ライフサイエンスコーパス: histiocytic

1 ons in the tumor microenvironment, featuring histiocytic accumulation and widespread tumor necrosis.

2 Rare cases of histiocytic and dendritic cell (H/DC) neoplasms have bee

3 ry pigmented nodular adrenocortical disease, histiocytic and epithelial hyperplasias, lymphomas, and

4 ethal systemic inflammation characterized by histiocytic and fibrotic tissue infiltration resembling

5 25%), histiocytic (n = 1, 13%), and combined histiocytic and sarcoidal (n = 1, 13%).

6 crophages in lymph node germinal centers and histiocytic and T lymphocyte infiltration in the lamina

7 c malignancies, including lymphoid, myeloid, histiocytic, and mast cell neoplasms.

8 oplasm and pleomorphic nuclei, and expressed histiocytic antigens in the absence of lymphocyte-specif

9 demonstrate a systemic lymphoplasmacytic and histiocytic arteritis and periarteritis in guinea pigs m

10 le xanthogranuloma (JXG) is a non-Langerhans histiocytic cell disorder in children which mostly affec

11 neonatal foreskin fibroblasts (HFF), and the histiocytic cell line U937 were cultured for designated

12 F4/80(+) and anti-mouse CD11b (Mac-1)(+) histiocytic cells predominated within the tumors.

13 ed caspase-3 immunopositivity in lymphocytic/histiocytic cells.

14 ns of ECD seen on multimodal imaging include histiocytic choroidal infiltration causing choroidal les

15 10/21 [48%]), and lymphomas with a prominent histiocytic component (6/7 [86%]).

16 ibitor, vemurafenib, in 3 patients with rare histiocytic conditions, Erdheim-Chester disease and Lang

17 nsdifferentiation and acquired expression of histiocytic/dendritic cell markers.

18 morphologic and immunophenotypic evidence of histiocytic differentiation.

19 sed therapeutic strategies for patients with histiocytic diseases.

20 Inclusion criteria were (1) histiocytic disorder by biopsy and appropriate clinical

21 Erdheim-Chester disease (ECD) is a rare histiocytic disorder that is challenging to diagnose and

22 olecular pathology, and clinical features of histiocytic disorders have been identified.

23 ) and Erdheim-Chester disease (ECD) are rare histiocytic disorders induced by somatic mutation of MAP

24 The "C group" of the histiocytic disorders is characterized by non-Langerhans

25 The etiology of many histiocytic disorders is unknown, but our findings sugge

26 d or refractory solid tumors, lymphomas, and histiocytic disorders to phase II studies of molecularly

27 All of the lesions from histiocytic disorders were characterized by an extremely

28 nguishable between LCH and ECD, although the histiocytic disorders were distinct to HCL.

29 with refractory solid tumors, lymphomas, or histiocytic disorders were subjected to cancer gene pane

30 The title of this Primer (Histiocytic disorders) was chosen to differentiate the a

31 tment strategies for some of the most common histiocytic disorders, including Langerhans cell histioc

32 Lesions from other histiocytic disorders, juvenile xanthogranuloma, Erdheim

33 Among the rare histiocytic disorders, xanthogranulomatosis is the commo

34 for the clinical management of this emerging histiocytic entity.

35 Lck-GM-CSF transgenic mice resemble those of histiocytic human diseases, such as Langerhans cell hist

36 The non-Langerhans' histiocytic infiltrate showed supportive immunohistochem

37 terized by a predominantly polymorphonuclear/histiocytic infiltrate that contained lymphocytes and pl

38 Control mice exhibited mild lymphocytic and histiocytic infiltrates, whereas GKO mice developed larg

39 the lamina propria by lymphoplasmacytic and histiocytic infiltrates.

40 ma cytokine levels and significantly reduces histiocytic infiltration and ceramide accumulation throu

41 nosis of ECD in 1 case, with the presence of histiocytic infiltration, fibrosis, and characteristic i

42 eflected extracellular-matrix deposition and histiocytic infiltration.

43 Initial neutrophilic and histiocytic inflammation in affected tissues became prog

44 r lumina of the epididymides, and in foci of histiocytic inflammation in the brain, but not in organs

45 ogy comparable to that of WT mice, increased histiocytic inflammation was observed in the uterine hor

46 Lungs of control mice manifested exuberant histiocytic inflammation with visible C. neoformans, fin

47 eas of crypt hyperplasia and a predominantly histiocytic inflammatory cell infiltrate.

48 achio-cervical inflammatory myopathy (BCIM); histiocytic inflammatory myopathies, like sarcoid myopat

49 Chronic histiocytic intervillositis (CHI) is a recurrent placent

50 e of placental histological lesions, such as histiocytic intervillositis and trophoblastic necrosis,

51 ed-Sternberg (H-RS) cells or lymphocytic and histiocytic (L&H) cells, respectively.

52 re is general agreement that lymphocytic and histiocytic (L&H) cells, the variants of Reed-Sternberg

53 ders is characterized by non-Langerhans-cell histiocytic lesions in the skin, mucosal surfaces, or bo

54 od borne precursors lead to the formation of histiocytic lesions.

55 mutation (MEK1(E102_I103del)) drove a lethal histiocytic-like neoplasm in mice, which was sensitive t

56 iated with Rhodococcus equi, including intra-histiocytic localization.

57 ) and chronic myelogenous (K-562) leukemias, histiocytic lymphoma (U-937), tongue (CAL 27) and pharyn

58 ibitor (Ki = 1 muM), decreases S1P levels in histiocytic lymphoma (U937) cells.

59 s transfected with full-length BAFF, or by a histiocytic lymphoma cell line (U937) that expresses BAF

60 The assay was evaluated with the histiocytic lymphoma cell line U937 and the topoisomeras

61 ol from primary human monocytes, human U-937 histiocytic lymphoma cells and from Chinese hamster ovar

62 ribed here found that adhesion of U937 human histiocytic lymphoma cells to FN provides a survival adv

63 Treatment of U937 human histiocytic lymphoma cells with E7389 led to time-depend

64 ) in IL-8 expression by "monocyte-like" U937 histiocytic lymphoma cells.

65 ct of LPS on TNF-mediated apoptosis in human histiocytic lymphoma U-937 cells was investigated.

66 4 on the cell surface TNF receptors in human histiocytic lymphoma U-937 cells.

67 We show that treatment of human histiocytic lymphoma U937 cells with the HIV-tat protein

68 ngth CD163 cDNAs from PAM, human U937 cells (histiocytic lymphoma), African green monkey kidney cells

69 ociated with rapid cell death in the diffuse histiocytic lymphoma, U937; Burkitt's lymphoma, ST486; b

70 True histiocytic lymphomas (THLs) are rare tumors in which th

71 otheliomas, osteosarcomas, sarcomas and true histiocytic lymphomas when injected in hamsters.

72 markers but showed a positive reactivity to histiocytic markers.

73 shes a novel, transplantable model of murine histiocytic/myeloid sarcoma that recapitulates the natur

74 t cell (n = 4, 50%), sarcoidal (n = 2, 25%), histiocytic (n = 1, 13%), and combined histiocytic and s

75 angerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm associated with somatic mutations i

76 -positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 in 3 infant

77 Juvenile xanthogranuloma (JXG) is a histiocytic neoplasm that usually presents in the skin.

78 Rosai-Dorfman disease (RDD) is a rare histiocytic neoplasm with recent studies showing alterat

79 erived xenotransplantation model for a human histiocytic neoplasm.

80 ferential diagnoses include fibroblastic and histiocytic neoplasm.

81 tudy advances the molecular understanding of histiocytic neoplasms and may guide diagnostics and clin

82 Histiocytic neoplasms are a heterogeneous group of clona

83 Collectively, these data demonstrate that histiocytic neoplasms are characterized by a notable dep

84 Histiocytic neoplasms are clonal disorders of the monocy

85 pothesized to be a consistent feature across histiocytic neoplasms, this remains clinically unproven

86 lassical hairy cell leukemia and a number of histiocytic neoplasms.

87 cancers or acute leukemia (460 [15.5%]), and histiocytic- or dendritic-cell cancers (129 [4.4%]).

88 e in the lysosome of macrophages, leading to histiocytic reaction in different organs.

89 Mild-to-severe lymphoid depletion and histiocytic replacement were detected in lymphoid tissue

90 (14%), 1 Erdheim-Chester disease (3%), and 1 histiocytic sarcoma (3%).

91 Moreover, murine histiocytic sarcoma could be similarly induced by intram

92 ce (mixed germ cell tumor, Triton tumor, and histiocytic sarcoma) also developed in Bax-/-ARF-/- anim

93 nts include primary myelofibrosis, leukemia, histiocytic sarcoma, and vasculitis.

94 i-Dorfman disease, juvenile xanthogranuloma, histiocytic sarcoma, xanthoma disseminatum, interdigitat

95 he systemic leukemic phenotypes exhibited by histiocytic sarcoma-bearing mice were nearly identical t

96 ing trans-differentiation into CD19-negative histiocytic sarcoma.

97 ematopoietic system in male and female mice (histiocytic sarcomas and malignant lymphomas), and ovary

98 tiple tumor phenotypes, including lymphomas, histiocytic sarcomas and, less frequently, mammary and h

99 The H/DC tumors included 7 histiocytic sarcomas, 5 of which showed evidence of dend

100 In this model, murine histiocytic sarcomas, equivalent to human myeloid sarcom

101 ouse tumors were classified as bone-invasive histiocytic sarcomas.

102 The histiocytic syndromes of childhood are disorders of the

103 or other malignant neoplasms of lymphoid and histiocytic tissue, 0.552 (95% CI [0.453,0.683]; P < .00

104 mphasizes the histopathological challenge of histiocytic tumours which may involve digestive track.

105 ith evidence of nonlymphoid neoplasia of the histiocytic type leading to death within 4 weeks of age.